Zacks Investment Research
24 Sept 2026, 17:51 UTC · 1h ago
Verdict
Headline takes no side. We score IMVT −0.60 across two claims — strongly bearish.
−0.60strongly bearish
More negative than 79% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
Immunovant discontinued its cutaneous lupus erythematosus (CLE) program after a proof-of-concept study of IMVT-1402 failed to achieve statistical significance on the primary endpoint.
Newannounced on Wednesday, Sep 24, 2026
So whatThe loss of this indication reduces the total addressable market for IMVT-1402, potentially lowering long-term peak sales estimates.
More negative than 95% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
The company expects top-line data from potentially registrational clinical studies for IMVT-1402 in Graves' disease (GD) and myasthenia gravis (MG).
Priced instanding guidance
More positive than 63% of claims this week
Which stocks this story touches
More negative than 79% of ticker scores this week
The company discontinued its CLE program after a study failed to achieve statistical significance, leading to a share price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3h ago
−1.2%
Price agrees with the score
$34.11 vs $34.54 close before publication (Sep 23) · not market-adjusted
IMVT chart →
